Certara (CERT) PEG Ratio: History & Chart

Certara, Inc.(CERT)

Medical - Healthcare Information Services · Radnor, PA

$10.06-0.01 (-0.10%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Certara, Inc.

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.

Radnor, PA

1,546 employees

www.certara.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Jon Resnick

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Certara, Inc. (CERT)	$1.56B	N/A	N/A	N/A	N/A
Eton Pharmaceuticals, Inc. (ETON)vs ›	$1.53B	N/A	N/A	N/A	N/A
Innoviva, Inc. (INVA)vs ›	$1.54B	0.49	0.51	1.07	0.57
GH Research PLC (GHRS)vs ›	$1.52B	N/A	N/A	N/A	N/A
Braveheart Bio, Inc. (BRVE)vs ›	$1.53B	N/A	N/A	N/A	N/A
Alphatec Holdings, Inc. (ATEC)vs ›	$1.66B	N/A	N/A	N/A	N/A
ANI Pharmaceuticals, Inc. (ANIP)vs ›	$1.66B	N/A	N/A	N/A	N/A
Kestra Medical Technologies, Ltd. (KMTS)vs ›	$1.68B	N/A	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.46B	N/A	N/A	N/A	N/A
Healthcare Services Group, Inc. (HCSG)vs ›	$1.47B	N/A	1.94	1.77	2.38

NAME

MARKET CAP

PEG RATIO

TTM

Certara, Inc. (CERT)

$1.56B

N/A

Eton Pharmaceuticals, Inc. (ETON)vs ›

$1.53B

N/A

Innoviva, Inc. (INVA)vs ›

$1.54B

0.49

0.51

1.07

0.57

GH Research PLC (GHRS)vs ›

$1.52B

N/A

Braveheart Bio, Inc. (BRVE)vs ›

$1.53B

N/A

Alphatec Holdings, Inc. (ATEC)vs ›

$1.66B

N/A

ANI Pharmaceuticals, Inc. (ANIP)vs ›

$1.66B

N/A

Kestra Medical Technologies, Ltd. (KMTS)vs ›

$1.68B

N/A

AnaptysBio, Inc. (ANAB)vs ›

$1.46B

N/A

Healthcare Services Group, Inc. (HCSG)vs ›

$1.47B

N/A

1.94

1.77

2.38

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

CERT PEG Ratio Metrics

CERT Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics